Guofei Zhou

Guofei Zhou

Auto-generated profile, based on publicly available information

Guofei Zhou

Department of Pediatrics

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JDJingbo Dai
Jingbo Dai
QZQiyuan Zhou
Qiyuan Zhou
JCJiwang Chen
Jiwang Chen
MRMegan L. Rexius-Hall
Megan L. Rexius-Hall
JRJalees Rehman
Jalees Rehman
GZGuofei Zhou
Guofei Zhou
The molecular mechanisms underlying the metabolic shift toward increased glycolysis observed in pulmonary artery smooth muscle cells (PASMC) during the pathogenesis of pulmonary arterial hypertension (PAH) are not fully understood. Here we show that the glycolytic enzyme α-enolase (ENO1) regulates the metabolic reprogramming and malignant phenotype of PASMC. We show that ENO1 levels are elevated in patients with associated PAH and in animal models of hypoxic pulmonary hypertension (HPH). The silencing or inhibition of ENO1 decreases PASMC proliferation and de-differentiation, and induces PASMC apoptosis, whereas the overexpression of ENO1 promotes a synthetic, de- differentiated, and apoptotic-resistant phenotype via the AMPK-Akt pathway. The suppression of ENO1 prevents the hypoxia-induced metabolic shift from mitochondrial respiration to glycolysis in PASMC. Finally, we find that pharmacological inhibition of ENO1 reverses HPH in mice and rats, suggesting ENO1 as a regulator of pathogenic metabolic reprogramming in HPH.

1 November 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
JCJiwang Chen
Jiwang Chen
HTHaiyang Tang
Haiyang Tang
JSJustin R. Sysol
Justin R. Sysol
LMLiliana Moreno-Vinasco
Liliana Moreno-Vinasco
KSKrystyna M. Shioura
Krystyna M. Shioura
RMRoberto F Machado
Roberto F Machado
Rationale: Sphingosine kinases (SphKs) 1 and 2 regulate the synthesis of the bioactive sphingolipid sphingosine-1-phosphate (S1P), an important lipid mediator that promotes cell proliferation, migration, and angiogenesis. Objectives: We aimed to examine whether SphKs and their product, S1P, play a role in the development of pulmonary arterial hypertension (PAH). Methods: SphK1 −/− , SphK2−/−, and S1P lyase heterozygous (Sgpl1+/−) mice, a pharmacologic SphK inhibitor (SKI2), and a S1P receptor 2 (S1PR2) antagonist (JTE013) were used in rodent models of hypoxia-mediated pulmonary hypertension (HPH). S1P levels in lung tissues from patients with PAH and pulmonary arteries (PAs) from rodent models of HPH were measured. Measurements and Main Results: mRNA and protein levels of SphK1, but not SphK2, were significantly increased in the lungs and isolated PA smooth muscle cells (PASMCs) from patients with PAH, and in lungs of experimental rodent models of HPH. S1P levels were increased in lungs of patients with PAH and PAs from rodent models of HPH. Unlike SphK2−/− mice, SphK1−/− mice were protected against HPH, whereas Sgpl1+/− mice were more susceptible to HPH. Pharmacologic SphK1 and S1PR2 inhibition prevented the development of HPH in rodent models of HPH. Overexpression of SphK1 and stimulation with S1P potentially via ligation of S1PR2 promoted PASMC proliferation in vitro, whereas SphK1 deficiency inhibited PASMC proliferation. Conclusions: The SphK1/S1P axis is a novel pathway in PAH that promotes PASMC proliferation, a major contributor to pulmonary vascular remodeling. Our results suggest that this pathway is a potential therapeutic target in PAH.

1 October 2013 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
JIJoyce Christina F. Ibe
Joyce Christina F. Ibe
QZQiyuan Zhou
Qiyuan Zhou
TCTianji Chen
Tianji Chen
HTHaiyang Tang
Haiyang Tang
JYJason X.-J. Yuan
Jason X.-J. Yuan
GZGuofei Zhou
Guofei Zhou
Human pulmonary artery smooth muscle cells (HPASMCs) express both adenosine monophosphate–activated protein kinase (AMPK) α1 and α2. We investigated the distinct roles of AMPK α1 and α2 in the survival of HPASMCs during hypoxia and hypoxia-induced pulmonary hypertension (PH). The exposure of HPASMCs to hypoxia (3% O2) increased AMPK activation and phosphorylation, and the inhibition of AMPK with Compound C during hypoxia decreased their viability and increased lactate dehydrogenase activity and apoptosis. Although the suppression of either AMPK α1 or α2 expression led to increased cell death, the suppression of AMPK α2 alone increased caspase-3 activity and apoptosis in HPASMCs exposed to hypoxia. It also resulted in the decreased expression of myeloid cell leukemia sequence 1 (MCL-1). The knockdown of MCL-1 or MCL-1 inhibitors increased caspase-3 activity and apoptosis in HPASMCs exposed to hypoxia. On the other hand, the suppression of AMPK α1 expression alone prevented hypoxia-mediated autophagy. The inhibition of autophagy induced cell death in HPASMCs. Our results suggest that AMPK α1 and AMPK α2 play differential roles in the survival of HPASMCs during hypoxia. The activation of AMPK α2 maintains the expression of MCL-1 and prevents apoptosis, whereas the activation of AMPK α1 stimulates autophagy, promoting HPASMC survival. Moreover, treatment with Compound C, which inhibits both isoforms of AMPK, prevented and partly reversed hypoxia-induced PH in mice. Taking these results together, our study suggests that AMPK plays a key role in the pathogenesis of pulmonary arterial hypertension, and AMPK may represent a novel therapeutic target for the treatment of pulmonary arterial hypertension.

15 March 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
TCTianji Chen
Tianji Chen
GZGuofei Zhou
Guofei Zhou
QZQiyuan Zhou
Qiyuan Zhou
HTHaiyang Tang
Haiyang Tang
JIJoyce Christina F. Ibe
Joyce Christina F. Ibe
URUsha Raj
Usha Raj
Rationale: Recent studies suggest that microRNAs (miRNAs) play important roles in regulation of pulmonary artery smooth muscle cell (PASMC) phenotype and are implicated in pulmonary arterial hypertension (PAH). However, the underlying molecular mechanisms remain elusive. Objectives: This study aims to understand the mechanisms regulating PASMC proliferation and differentiation by microRNA-17∼92 (miR-17∼92) and to elucidate its implication in PAH. Methods: We generated smooth muscle cell (SMC)-specific miR-17∼92 and PDZ and LIM domain 5 (PDLIM5) knockout mice and overexpressed miR-17∼92 and PDLIM5 by injection of miR-17∼92 mimics or PDLIM5-V5-His plasmids and measured their responses to hypoxia. We used miR-17∼92 mimics, inhibitors, overexpression vectors, small interfering RNAs against PDLIM5, Smad, and transforming growth factor (TGF)-β to determine the role of miR-17∼92 and its downstream targets in PASMC proliferation and differentiation. Measurements and Main Results: We found that human PASMC (HPASMC) from patients with PAH expressed decreased levels of the miR-17∼92 cluster, TGF-β, and SMC markers. Overexpression of miR-17∼92 increased and restored the expression of TGF-β3, Smad3, and SMC markers in HPASMC of normal subjects and patients with idiopathic PAH, respectively. Knockdown of Smad3 but not Smad2 prevented miR-17∼92-induced expression of SMC markers. SMC-specific knockout of miR-17∼92 attenuated hypoxia-induced pulmonary hypertension (PH) in mice, whereas reconstitution of miR-17∼92 restored hypoxia-induced PH in these mice. We also found that PDLIM5 is a direct target of miR-17/20a, and hypertensive HPASMC and mouse PASMC expressed elevated PDLIM5 levels. Suppression of PDLIM5 increased expression of SMC markers and enhanced TGF-β/Smad2/3 activity in vitro and enhanced hypoxia-induced PH in vivo, whereas overexpression of PDLIM5 attenuated hypoxia-induced PH. Conclusions: We provided the first evidence that miR-17∼92 inhibits PDLIM5 to induce the TGF-β3/SMAD3 pathway, contributing to the pathogenesis of PAH.

1 December 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TCTianji Chen
Tianji Chen
QZQiyuan Zhou
Qiyuan Zhou
HTHaiyang Tang
Haiyang Tang
MBMelike Bozkanat
Melike Bozkanat
JYJason X.‐J. Yuan
Jason X.‐J. Yuan
GZGuofei Zhou
Guofei Zhou
Background: Previously we found that smooth muscle cell ( SMC )‐specific knockout of miR‐17~92 attenuates hypoxia‐induced pulmonary hypertension. However, the mechanism underlying miR‐17~92‐mediated pulmonary artery SMC ( PASMC ) proliferation remains unclear. We sought to investigate whether miR‐17~92 regulates hypoxia‐inducible factor ( HIF ) activity and PASMC proliferation via prolyl hydroxylases ( PHD s). Methods and Results: We show that hypoxic sm‐17~92 −/− mice have decreased hematocrit, red blood cell counts, and hemoglobin contents. The sm‐17~92 −/− mouse lungs express decreased mRNA levels of HIF targets and increased levels of PHD 2. miR‐17~92 inhibitors suppress hypoxia‐induced levels of HIF 1α, VEGF , Glut1, HK 2, and PDK 1 but not HIF 2α in vitro in PASMC . Overexpression of miR‐17 in PASMC represses PHD 2 expression, whereas miR‐17/20a inhibitors induce PHD 2 expression. The 3′‐ UTR of PHD 2 contains a functional miR‐17/20a seed sequence. Silencing of PHD 2 induces HIF 1α and PCNA protein levels, whereas overexpression of PHD 2 decreases HIF 1α and cell proliferation. SMC ‐specific knockout of PHD 2 enhances hypoxia‐induced vascular remodeling and exacerbates established pulmonary hypertension in mice. PHD 2 activator R59949 reverses vessel remodeling in existing hypertensive mice. PHD s are dysregulated in PASMC isolated from pulmonary arterial hypertension patients. Conclusions: Our results suggest that PHD 2 is a direct target of miR‐17/20a and that miR‐17~92 contributes to PASMC proliferation and polycythemia by suppression of PHD 2 and induction of HIF 1α.

1 April 2012 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
ARAarti Raghavan
Aarti Raghavan
GZGuofei Zhou
Guofei Zhou
QZQiyuan Zhou
Qiyuan Zhou
JIJoyce Christina F. Ibe
Joyce Christina F. Ibe
RRRamaswamy Ramchandran
Ramaswamy Ramchandran
JRJ. Usha Raj
J. Usha Raj
Pulmonary arterial hypertension (PAH) is a devastating disease, and no effective treatments are available. Hypoxia-induced pulmonary artery remodeling, including smooth muscle cell proliferation, contributes to PAH, but the exact mechanisms underlying this abnormal process are largely undefined. The forkhead box M1 (FoxM1) transcription factor regulates cancer cell growth by modulating gene expression critical for cell cycle progression. Here, we report for the first time, to the best of our knowledge, a novel function of FoxM1 in the hypoxia-stimulated proliferation of human pulmonary artery smooth muscle cells (HPASMCs). Exposure to hypoxia caused a marked up-regulation of FoxM1 gene expression, mainly at the transcription level, and this induction correlated with HPASMC cell proliferation. The knockdown of FoxM1 inhibited the hypoxia-stimulated proliferation of HPASMCs. We found that the knockdown of HIF-2α, but not HIF-1α, diminished FoxM1 induction in response to hypoxia. However, the knockdown of FoxM1 did not alter expression levels of HIF-2α or HIF-1α, suggesting that HIF-2α is an upstream regulator of FoxM1. Furthermore, the knockdown of FoxM1 prevented the hypoxia-induced expression of aurora A kinase and cyclin D1. Collectively, our results suggest that hypoxia induces FoxM1 gene expression in an HIF-2α–dependent pathway, thereby promoting HPASMC proliferation.